Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the period ending July 2011. The report details a specific corporate action regarding share repurchases executed on July 8, 2011, pursuant to shareholder authority granted at the Annual General Meeting on May 5, 2011.
Key Financial Metrics
The filing does not provide standard financial performance metrics such as revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on capital structure changes related to share buybacks.
- Shares Purchased: 1,130,000 Ordinary shares of 25 pence each.
- Price Range: Highest price paid was 1,375.0 pence per share; lowest price paid was 1,362.0 pence per share.
- Treasury Holdings (Settled): 473,804,284 shares (8.46% of total issued share capital).
- Treasury Holdings (Including Unsettled): 477,434,284 shares (9.31% of total voting rights).
- Shares in Issue (Excluding Treasury): 5,129,013,958 shares.
Material Changes
The primary material change reported is the reduction of outstanding shares through the purchase of 1,130,000 shares. This transaction increased the Company's treasury holdings, raising the percentage of total voting rights held in treasury to 9.31% when including unsettled purchases.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, outlook, or discussion of risks and contingencies. The shares purchased are intended to be held in Treasury.
Investor Verification Checklist
- Verify the total number of shares held in Treasury (473,804,284 settled) against the total issued share capital to confirm the 8.46% ownership stake.
- Confirm the impact of the 9.31% treasury holding on total voting rights for regulatory disclosure thresholds under the Financial Services Authority's Disclosure and Transparency Rules.
- Review the price paid per share (1,362.0 to 1,375.0 pence) relative to the market price on July 8, 2011.
- Note that this filing does not contain operational or financial performance data; refer to Form 20-F for comprehensive financial statements.